Literature DB >> 6326110

Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion.

R L Hoover, M J Karnovsky, K F Austen, E J Corey, R A Lewis.   

Abstract

The attachment of human polymorphonuclear leukocytes (PMN) to bovine endothelial monolayers is increased by pretreatment of the endothelial cells with leukotriene B4 (LTB4). The response is dose dependent with a maximum at 10(-6) M, requires no more than 1 min of preincubation for the maximal effect, and decays linearly over 30 min once the LTB4 is removed. Preincubation of PMN with LTB4 does not augment subsequent adhesion to a plastic substratum or an untreated monolayer of endothelial cells and eliminates the augmented attachment to LTB4-pretreated endothelial cells. The simultaneous exposure of both cell types during the adhesion interaction gives a biphasic dose-related increment, suggesting that the inhibition of the neutrophil adherence is less marked than with a pretreatment interval. Thus, the LTB4-dependent adherence of PMN to endothelial cells is selectively mediated by endothelial cells, is dose related, is reversible upon removal of the agonist from the endothelial cells, and is opposed by the direct action of LTB4 on the PMN.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326110      PMCID: PMC345463          DOI: 10.1073/pnas.81.7.2191

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  A quantitative assay for intercellular adhesion.

Authors:  B T Walther; R Ohman; S Roseman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-05       Impact factor: 11.205

Review 2.  Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds.

Authors:  R A Lewis; K F Austen
Journal:  Nature       Date:  1981 Sep 10-16       Impact factor: 49.962

3.  Structure of slow-reacting substance of anaphylaxis from guinea-pig lung.

Authors:  H R Morris; G W Taylor; P J Piper; J R Tippins
Journal:  Nature       Date:  1980-05-08       Impact factor: 49.962

4.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

5.  Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids.

Authors:  P Borgeat; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

6.  Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources.

Authors:  R A Lewis; K F Austen; J M Drazen; D A Clark; A Marfat; E J Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

7.  Inhibition of leukotriene C and leukotriene D biosynthesis.

Authors:  L Orning; S Hammarström
Journal:  J Biol Chem       Date:  1980-09-10       Impact factor: 5.157

8.  Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence.

Authors:  J Palmblad; C L Malmsten; A M Udén; O Rådmark; L Engstedt; B Samuelsson
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

9.  Adhesion of leukocytes to endothelium: roles of divalent cations, surface charge, chemotactic agents and substrate.

Authors:  R L Hoover; R Folger; W A Haering; B R Ware; M J Karnovsky
Journal:  J Cell Sci       Date:  1980-10       Impact factor: 5.285

10.  Functional characterization of synthetic leukotriene B and its stereochemical isomers.

Authors:  R A Lewis; E J Goetzl; J M Drazen; N A Soter; K F Austen; E J Corey
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  56 in total

1.  Priming effects of leukotriene B4 on endothelial cell injury induced by TPA-activated leukocytes.

Authors:  N Suda; I Morita; T Kuroda; S Murota
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

Review 2.  The pharmacology of ebselen.

Authors:  M J Parnham; S Leyck; E Graf; E J Dowling; D R Blake
Journal:  Agents Actions       Date:  1991-01

3.  Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187.

Authors:  R Roubin; P P Elsas; W Fiers; A J Dessein
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

4.  Neutrophil adherence to human endothelium in vitro occurs by CDw18 (Mo1, MAC-1/LFA-1/GP 150,95) glycoprotein-dependent and -independent mechanisms.

Authors:  G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

5.  Synergistic effects of LTB4 and LTD4 on leukocyte emigration into the guinea pig conjunctiva.

Authors:  C S Spada; D F Woodward; S B Hawley; A L Nieves; L S Williams; B J Feldmann
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

6.  Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits.

Authors:  N J Jansen; W van Oeveren; B H Hoiting; C R Wildevuur
Journal:  Inflammation       Date:  1991-04       Impact factor: 4.092

Review 7.  PMN adhesion and extravasation as a paradigm for tumor cell dissemination.

Authors:  C W Smith; D C Anderson
Journal:  Cancer Metastasis Rev       Date:  1991-05       Impact factor: 9.264

8.  Ceruloplasmin reduces the adhesion and scavenges superoxide during the interaction of activated polymorphonuclear leukocytes with endothelial cells.

Authors:  C Broadley; R L Hoover
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

9.  Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis.

Authors:  D J Fretland; D L Widomski; J M Zemaitis; S W Djurić; R L Shone
Journal:  Inflammation       Date:  1989-10       Impact factor: 4.092

10.  The role of interleukin-1 in neutrophil leukocyte emigration induced by endotoxin.

Authors:  M I Cybulsky; I G Colditz; H Z Movat
Journal:  Am J Pathol       Date:  1986-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.